Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 2/2015

01-02-2015 | Original Paper

Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies

Authors: Xu Yao, Zhong Tian

Published in: Cancer Causes & Control | Issue 2/2015

Login to get access

Abstract

Purpose

The findings from epidemiologic studies of dyslipidemia and colorectal cancer risk have been conflicting. We performed a dose–response meta-analysis of published prospective studies to assess the aforementioned association.

Methods

Relevant studies that reported the association between the components of dyslipidemia (serum triglyceride, total cholesterol, and high-/low-density lipoprotein cholesterol) and colorectal cancer risk were identified by searching PubMed until the end of May 2014. We pooled the relative risks (RRs) from individual studies using a random- and fixed-effects models and performed dose–response, heterogeneity, and publication bias analyses.

Results

Seventeen prospective studies, including 1,987,753 individuals with 10,876 colorectal cancer events, were included in the meta-analysis. The overall pooled RR for high versus low concentrations for triglyceride (n = 9 studies) was 1.18 (95 % CI 1.04–1.34; I 2 = 47.8 %), for total cholesterol (n = 10 studies) was 1.11 (95 % CI 1.01–1.21; I 2 = 46.7 %), for high-density lipoprotein cholesterol (n = 6 studies) was 0.84 (95 % CI 0.69–1.02; I 2 = 42.5 %), and for low-density lipoprotein cholesterol (n = 3 studies) was 1.04 (95 % CI 0.60–1.81; I 2 = 82.7 %). In the dose–response analysis, the overall pooled RR was 1.01 (95 % CI 1.00–1.03; I 2 = 0 %) per 50 mg/dL of triglyceride and 1.01 (95 % CI 0.97–1.05; I 2 = 64.3 %) per 100 mg/dL of total cholesterol.

Conclusions

This meta-analysis of prospective studies suggests that dyslipidemia, especially high levels of serum triglyceride and total cholesterol, is associated with an increased risk of colorectal cancer, whereas high-density lipoprotein cholesterol might associate with a decreased risk of colorectal cancer. Further studies are warranted to determine whether altering the concentrations of these metabolic variables may reduce colorectal cancer risk.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. International agency for research on cancer, Lyon, France. http://​globocan.​iarc.​fr. Accessed 14 July 2014
2.
World Cancer Resarch Fund/American Institue for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: a global perspective. AICR, Washington
3.
4.
Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:s836–s842PubMed
5.
Esteve E, Ricart W, Fernandez-Real JM (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 24:16–31PubMedCrossRef
6.
Kontush A, de Faria EC, Chantepie S, Chapman MJ (2005) A normotriglyceridemic, low HDL–cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182:277–285PubMedCrossRef
7.
Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z et al (2007) Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 37:715–723PubMedCrossRef
8.
Avramoglu RK, Basciano H, Adeli K (2006) Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 368:1–19PubMedCrossRef
9.
Ghandehari H, Kamal-Bahl S, Wong ND (2008) Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 156:112–119PubMedCrossRef
10.
Rosamond W, Flegal K, Furie K et al (2008) Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146PubMedCrossRef
11.
Ford ES, Mokdad AH, Giles WH, Mensah GA (2003) Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 107:2185–2189PubMedCrossRef
12.
Borena W, Stocks T, Jonsson H et al (2011) Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 22:291–299PubMedCrossRef
13.
Inoue M, Noda M, Kurahashi N et al (2009) Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 18:240–247PubMedCrossRef
14.
Tulinius H, Sigfusson N, Sigvaldason H et al (1997) Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 6:863–873PubMed
15.
Agnoli C, Grioni S, Sieri S et al (2014) Colorectal cancer risk and dyslipidemia: a case–cohort study nested in an Italian multicentre cohort. Cancer Epidemiol 38:144–151PubMedCrossRef
16.
Kitahara CM, Berrington DGA, Freedman ND et al (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29:1592–1598PubMedCentralPubMedCrossRef
17.
Tornberg SA, Holm LE, Carstensen JM, Eklund GA (1986) Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med 315:1629–1633PubMedCrossRef
18.
Strohmaier S, Edlinger M, Manjer J et al (2013) Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One 8:e54242PubMedCentralPubMedCrossRef
19.
van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M et al (2011) Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European prospective investigation into cancer and nutrition. Gut 60:1094–1102PubMedCrossRef
20.
Ahn J, Lim U, Weinstein SJ et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18:2814–2821PubMedCentralPubMedCrossRef
21.
Iso H, Ikeda A, Inoue M et al (2009) Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 125:2679–2686PubMedCrossRef
22.
Ahmed RL, Schmitz KH, Anderson KE et al (2006) The metabolic syndrome and risk of incident colorectal cancer. Cancer 107:28–36PubMedCrossRef
23.
Bowers K, Albanes D, Limburg P et al (2006) A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164:652–664PubMedCrossRef
24.
Tsushima M, Nomura AM, Lee J, Stemmermann GN (2005) Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci 50:499–505PubMedCrossRef
25.
Saydah SH, Platz EA, Rifai N et al (2003) Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 12:412–418PubMed
26.
Schoen RE, Tangen CM, Kuller LH et al (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91:1147–1154PubMedCrossRef
27.
Chyou PH, Nomura AM, Stemmermann GN (1996) A prospective study of colon and rectal cancer among Hawaii Japanese men. Ann Epidemiol 6:276–282PubMedCrossRef
28.
Esposito K, Chiodini P, Capuano A et al (2013) Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44:634–647PubMedCrossRef
29.
Law MR, Thompson SG (1991) Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 2:253–261PubMedCrossRef
30.
Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:s836–s842PubMed
31.
Kritchevsky SB, Kritchevsky D (1992) Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12:391–416PubMedCrossRef
32.
33.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 339:b2535
34.
Schatzkin A, Hoover RN, Taylor PR et al (1988) Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res 48:452–458PubMed
35.
36.
Wu QJ, Yang Y, Vogtmann E et al (2013) Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol 24:1079–1087PubMedCentralPubMedCrossRef
37.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
38.
39.
Hamling J, Lee P, Weitkunat R, Ambuhl M (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27:954–970PubMedCrossRef
40.
Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482PubMedCrossRef
41.
Chene G, Thompson SG (1996) Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 144:610–621PubMedCrossRef
42.
Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301–1309PubMed
43.
Orsini N, Li R, Wolk A et al (2012) Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 175:66–73PubMedCentralPubMedCrossRef
44.
Royston P (2000) A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med 19:1831–1847PubMedCrossRef
45.
Bagnardi V, Zambon A, Quatto P, Corrao G (2004) Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol 159:1077–1086PubMedCrossRef
46.
47.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRef
48.
Esposito K, Chiodini P, Capuano A et al (2013) Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20:1301–1309PubMedCrossRef
49.
Esposito K, Chiodini P, Capuano A et al (2013) Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 36:132–139PubMedCrossRef
50.
51.
Sugai T, Habano W, Jiao YF et al (2006) Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn 8:193–201PubMedCentralPubMedCrossRef
52.
van Stiphout WA, Hofman A, de Bruijn AM (1987) Serum lipids in young women before, during, and after pregnancy. Am J Epidemiol 126:922–928PubMed
53.
Munzer T, Harman SM, Sorkin JD, Blackman MR (2009) Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men. J Clin Endocrinol Metab 94:3833–3841PubMedCentralPubMedCrossRef
54.
Kumagai S, Kai Y, Sasaki H (2001) Relationship between insulin resistance, sex hormones and sex hormone-binding globulin in the serum lipid and lipoprotein profiles of Japanese postmenopausal women. J Atheroscler Thromb 8:14–20PubMedCrossRef
55.
McKeown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3:687–695PubMed
56.
Esteve E, Ricart W, Fernandez-Real JM (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 24:16–31PubMedCrossRef
57.
58.
59.
60.
van Exel E, Gussekloo J, de Craen AJ et al (2002) Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study. Diabetes 51:1088–1092PubMedCrossRef
61.
Kontush A, de Faria EC, Chantepie S, Chapman MJ (2005) A normotriglyceridemic, low HDL–cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182:277–285PubMedCrossRef
62.
Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z et al (2007) Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 37:715–723PubMedCrossRef
63.
Clarke R, Shipley M, Lewington S et al (1999) Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341–353PubMedCrossRef
64.
Al-Delaimy WK, Jansen EH, Peeters PH et al (2006) Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers 11:370–382PubMedCrossRef
65.
Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462–3468PubMedCrossRef
66.
Cole BF, Logan RF, Halabi S et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266PubMedCrossRef
Metadata
Title
Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies
Authors
Xu Yao
Zhong Tian
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 2/2015
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0507-y

Other articles of this Issue 2/2015

Cancer Causes & Control 2/2015 Go to the issue

Brief report

Dietary lignan intake and androgen receptor expression in breast tumors

Original Paper

Breast cancer mortality in relation to receipt of screening mammography: a case–control study in Saskatchewan, Canada

Original paper

Aberrant methylation of miR-34b is associated with long-term shiftwork: a potential mechanism for increased breast cancer susceptibility

Brief report

Type 2 diabetes and mammographic breast density among underserved women

Brief report

Lifetime alcohol consumption and upper aero-digestive tract cancer risk in the Melbourne Collaborative Cohort Study

Original Paper

Effects of supervised exercise on progression-free survival in lymphoma patients: an exploratory follow-up of the HELP Trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits